Impaired functional vitamin B6 status is associated with increased risk of lung cancer

D Theofylaktopoulou; Ø Midttun; PM Ueland; K Meyer; A Fanidi; W Zheng; XO Shu; YB Xiang; R Prentice; M Pettinger; CA Thomson; GG Giles; A Hodge; Q Cai; WJ Blot; J Wu; M Johansson; J Hultdin; K Grankvist; VL Stevens; MM McCullough; SJ Weinstein; D Albanes; R Ziegler; ND Freedman; A Langhammer; K Hveem; M Næss; HD Sesso; JM Gaziano; JE Buring; IM Lee; G Severi; X Zhang; MJ Stampfer; J Han; SA Smith-Warner; A Zeleniuch-Jacquotte; L Le Marchand; JM Yuan; R Wang; LM Butler; WP Koh; YT Gao; N Rothman; U Ericson; E Sonestedt; K Visvanathan; MR Jones; C Relton; P Brennan; M Johansson; A Ulvik

Journal article

Impaired functional vitamin B6 status is associated with increased risk of lung cancer

D Theofylaktopoulou, Ø Midttun, PM Ueland, K Meyer, A Fanidi, W Zheng, XO Shu, YB Xiang, R Prentice, M Pettinger, CA Thomson, GG Giles, A Hodge, Q Cai, WJ Blot, J Wu, M Johansson, J Hultdin, K Grankvist, VL Stevens Show all

International Journal of Cancer | WILEY | Published : 2018

DOI: 10.1002/ijc.31215

Download PDF

Abstract

Circulating vitamin B6 levels have been found to be inversely associated with lung cancer. Most studies have focused on the B6 form pyridoxal 5′-phosphate (PLP), a direct biomarker influenced by inflammation and other factors. Using a functional B6 marker allows further investigation of the potential role of vitamin B6 status in the pathogenesis of lung cancer. We prospectively evaluated the association of the functional marker of vitamin B6 status, the 3-hydroxykynurenine:xanthurenic acid (HK:XA) ratio, with risk of lung cancer in a nested case–control study consisting of 5,364 matched case–control pairs from the Lung Cancer Cohort Consortium (LC3). We used conditional logistic regression t..

View full abstract

University of Melbourne Researchers

Graham Giles Author

Allison Hodge Author

Grants

Awarded by State of Maryland

Funding Acknowledgements

Grant sponsor: NIH/NCI; Grant number: 1U01CA155340-01; Grant sponsor: Australian National Health and Medical Research Committee; Grant number: 1050198; Grant sponsor: National Cancer Institute; Grant numbers: R37 CA070867, UM1 CA182910, R01 CA082729, UM1 CA173640, R01 CA092447, U01 CA202979, U01 CA164973; Grant sponsors: National Institutes of Health, National Cancer Institute, Department of Health and Human Services, the State of Maryland, the Maryland Cigarette Restitution Fund, the National Program of Cancer Registries of the Centers for Disease Control and Prevention, Division of Cancer Prevention, Division of Cancer Epidemiology and Genetics, U.S. National Institutes of Health (NIH); Grant numbers: UM1CA167552, UM1CA186107, P01CA87969, R01CA49449; Grant sponsor: CRUK; Grant number: C18281/A19169; Grant sponsor: MRC; Grant number: MC_UU_12013/2; Grant sponsor: University of Bristol